Metz Terrence, Jones Mitchell L, Chen Hongmei, Halim Trisnawati, Mirzaei Maryam, Haque Tasima, Amre Devendra, Das Sujata K, Prakash Satya
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Physiology, Artificial Cells & Organs Research Center, Faculty of Medicine, McGill University, Montreal, Quebec, H3A 2B4, Canada.
Cell Biochem Biophys. 2005;43(1):77-85. doi: 10.1385/CBB:43:1:077.
Recent research and clinical evidence suggest that thalidomide could potentially be used to treat inflammation associated with Crohn's disease. However, systemic side effects associated with large doses of this drug have limited its widespread use. Treatment with thalidomide would prove more efficacious if the drug could be delivered directly to target areas in the gut, thereby reducing systemic circulation. Microcapsule encapsulation could enable direct delivery of the drug. To assess the latter, we designed and tested drug-targeting release characteristics of alginate-poly-L-lysine-alginate (APA) microcapsules in simulated gastrointestinal environments. The results show that APA capsules enabled delivery of thalidomide in the middle and distal portions of the small intestine. We also compared the APA membrane formulation with an earlier designed alginate chitosan (AC) membrane thalidomide formulation. The results show that both APA and AC capsules allow for successful delivery of thalidomide in the gut and could prove beneficial in the treatment of Crohn's disease. However, further research is required.
近期的研究和临床证据表明，沙利度胺可能可用于治疗与克罗恩病相关的炎症。然而，大剂量使用该药物所产生的全身性副作用限制了其广泛应用。如果能将沙利度胺直接输送至肠道的靶区域，从而减少其在全身的循环，那么用沙利度胺进行治疗将更具疗效。微胶囊包封能够实现药物的直接输送。为评估后者，我们设计并测试了海藻酸钠-聚-L-赖氨酸-海藻酸钠（APA）微胶囊在模拟胃肠道环境中的药物靶向释放特性。结果表明，APA胶囊能够在小肠的中部和远端实现沙利度胺的输送。我们还将APA膜制剂与早期设计的海藻酸钠-壳聚糖（AC）膜沙利度胺制剂进行了比较。结果表明，APA和AC胶囊都能在肠道中成功实现沙利度胺的输送，并且可能对克罗恩病的治疗有益。然而，仍需进一步研究。
Zotero 插件